Literature DB >> 24994929

Improved modeling of in vivo kinetics of slowly diffusing radiotracers for tumor imaging.

Moses Q Wilks1, Scott M Knowles2, Anna M Wu2, Sung-Cheng Huang3.   

Abstract

UNLABELLED: Large-molecule tracers, such as labeled antibodies, have shown success in immuno-PET for imaging of specific cell surface biomarkers. However, previous work has shown that localization of such tracers shows high levels of heterogeneity in target tissues, due to both the slow diffusion and the high affinity of these compounds. In this work, we investigate the effects of subvoxel spatial heterogeneity on measured time-activity curves in PET imaging and the effects of ignoring diffusion limitation on parameter estimates from kinetic modeling.
METHODS: Partial differential equations (PDE) were built to model a radially symmetric reaction-diffusion equation describing the activity of immuno-PET tracers. The effects of slower diffusion on measured time-activity curves and parameter estimates were measured in silico, and a modified Levenberg-Marquardt algorithm with Bayesian priors was developed to accurately estimate parameters from diffusion-limited data. This algorithm was applied to immuno-PET data of mice implanted with prostate stem cell antigen-overexpressing tumors and injected with (124)I-labeled A11 anti-prostate stem cell antigen minibody.
RESULTS: Slow diffusion of tracers in linear binding models resulted in heterogeneous localization in silico but no measurable differences in time-activity curves. For more realistic saturable binding models, measured time-activity curves were strongly dependent on diffusion rates of the tracers. Fitting diffusion-limited data with regular compartmental models led to parameter estimate bias in an excess of 1,000% of true values, while the new model and fitting protocol could accurately measure kinetics in silico. In vivo imaging data were also fit well by the new PDE model, with estimates of the dissociation constant (Kd) and receptor density close to in vitro measurements and with order of magnitude differences from a regular compartmental model ignoring tracer diffusion limitation.
CONCLUSION: Heterogeneous localization of large, high-affinity compounds can lead to large differences in measured time-activity curves in immuno-PET imaging, and ignoring diffusion limitations can lead to large errors in kinetic parameter estimates. Modeling of these systems with PDE models with Bayesian priors is necessary for quantitative in vivo measurements of kinetics of slow-diffusion tracers.
© 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  immuno-PET; minibody; prostate stem cell antigen (PSCA); quantitative imaging

Mesh:

Substances:

Year:  2014        PMID: 24994929      PMCID: PMC4334373          DOI: 10.2967/jnumed.114.140038

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  34 in total

1.  Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention.

Authors:  Christilyn P Graff; K Dane Wittrup
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

2.  Comparisons between two monoclonal antibodies that bind to the same antigen but have differing affinities: uptake kinetics and 125I-antibody therapy efficacy in multicell spheroids.

Authors:  V K Langmuir; H L Mendonca; D V Woo
Journal:  Cancer Res       Date:  1992-09-01       Impact factor: 12.701

Review 3.  Arming antibodies: prospects and challenges for immunoconjugates.

Authors:  Anna M Wu; Peter D Senter
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

4.  Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.

Authors:  Vania Kenanova; Tove Olafsen; Desiree M Crow; Gobalakrishnan Sundaresan; Murugesan Subbarayan; Nora H Carter; David N Ikle; Paul J Yazaki; Arion F Chatziioannou; Sanjiv S Gambhir; Lawrence E Williams; John E Shively; David Colcher; Andrew A Raubitschek; Anna M Wu
Journal:  Cancer Res       Date:  2005-01-15       Impact factor: 12.701

Review 5.  Antibodies and antimatter: the resurgence of immuno-PET.

Authors:  Anna M Wu
Journal:  J Nucl Med       Date:  2008-12-17       Impact factor: 10.057

6.  Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer.

Authors:  R E Reiter; Z Gu; T Watabe; G Thomas; K Szigeti; E Davis; M Wahl; S Nisitani; J Yamashiro; M M Le Beau; M Loda; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

Review 7.  PET imaging with ⁸⁹Zr: from radiochemistry to the clinic.

Authors:  Melissa A Deri; Brian M Zeglis; Lynn C Francesconi; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2012-09-19       Impact factor: 2.408

8.  PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma.

Authors:  S M Larson; K S Pentlow; N D Volkow; A P Wolf; R D Finn; R M Lambrecht; M C Graham; G Di Resta; B Bendriem; F Daghighian
Journal:  J Nucl Med       Date:  1992-11       Impact factor: 10.057

9.  Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors.

Authors:  Jeffrey V Leyton; Tove Olafsen; Eric J Lepin; Scott Hahm; Karl B Bauer; Robert E Reiter; Anna M Wu
Journal:  Clin Cancer Res       Date:  2008-11-15       Impact factor: 12.531

10.  Theoretic criteria for antibody penetration into solid tumors and micrometastases.

Authors:  Greg M Thurber; Stefan C Zajic; K Dane Wittrup
Journal:  J Nucl Med       Date:  2007-05-15       Impact factor: 10.057

View more
  7 in total

1.  Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.

Authors:  Aaron T Mayer; Arutselvan Natarajan; Sydney R Gordon; Roy L Maute; Melissa N McCracken; Aaron M Ring; Irving L Weissman; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2016-12-15       Impact factor: 10.057

Review 2.  Quantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imaging.

Authors:  Kenneth M Tichauer; Yu Wang; Brian W Pogue; Jonathan T C Liu
Journal:  Phys Med Biol       Date:  2015-07-02       Impact factor: 3.609

3.  Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers.

Authors:  Jimson W D'Souza; Harvey Hensley; Mohan Doss; Charles Beigarten; Michael Torgov; Tove Olafsen; Jian Q Yu; Matthew K Robinson
Journal:  J Nucl Med       Date:  2016-08-18       Impact factor: 10.057

4.  Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer.

Authors:  Scott M Knowles; Richard Tavaré; Kirstin A Zettlitz; Matthew M Rochefort; Felix B Salazar; Ziyue Karen Jiang; Robert E Reiter; Anna M Wu
Journal:  Clin Cancer Res       Date:  2014-10-17       Impact factor: 12.531

5.  Radiopharmaceuticals as Novel Immune System Tracers.

Authors:  Natalie A Ridge; Anne Rajkumar-Calkins; Stephanie O Dudzinski; Austin N Kirschner; Neil B Newman
Journal:  Adv Radiat Oncol       Date:  2022-06-18

6.  Quantification of the binding potential of cell-surface receptors in fresh excised specimens via dual-probe modeling of SERS nanoparticles.

Authors:  Lagnojita Sinha; Yu Wang; Cynthia Yang; Altaz Khan; Jovan G Brankov; Jonathan T C Liu; Kenneth M Tichauer
Journal:  Sci Rep       Date:  2015-02-26       Impact factor: 4.379

7.  Reproducible quantification of cardiac sympathetic innervation using graphical modeling of carbon-11-meta-hydroxyephedrine kinetics with dynamic PET-CT imaging.

Authors:  Tong Wang; Kai Yi Wu; Robert C Miner; Jennifer M Renaud; Rob S B Beanlands; Robert A deKemp
Journal:  EJNMMI Res       Date:  2018-07-20       Impact factor: 3.138

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.